Zhou Jingmin, Xu Jinshan, Cheng Lin, Li Shuhui, Jiang Deqi, Zhang Jianchao, Sheng Yulong
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Int J Biol Markers. 2024 Dec;39(4):284-291. doi: 10.1177/03936155241281076. Epub 2024 Sep 5.
Exploring effect biomarkers that monitor tumor progression and predict the prognosis could benefit the clinical management of bladder cancer and improve the postoperative life of patients. This study aimed to estimate the function of long non-coding (lnc)RNA RHPN1-AS1 (RHPN1-AS1) in bladder cancer and the potential molecular mechanism.
The expression of RHPN1-AS1 was evaluated in bladder cancer tissues from 115 patients and cells by polymerase chain reaction. The clinical significance of RHPN1-AS1 was assessed and its effect was also estimated in cell proliferation, migration, and invasion. The underlying molecular mechanism was explored by the dual-luciferase reporter assay.
The expression of RHPN1-AS1 was 2.91-fold elevated in bladder cancer, which showed a close correlation with advanced tumor node metastasis stage (= 0.013) and the presence of lymph node metastasis (= 0.018). RHPN1-AS1 also served as a poor prognostic indicator (hazard ratio = 2.563) for bladder cancer. The knockdown of RHPN1-AS1 significantly suppressed the proliferation and metastasis ability of bladder cancer cells. Moreover, miR-485-5p was found to mediate the function of RHPN1-AS1 in bladder cancer, which was considered the underlying regulatory mechanism.
RHPN1-AS1 serves as a prognostic biomarker and tumor promoter in bladder cancer via modulating miR-485-5p, which might be a reliable target of bladder cancer therapy.
探索可监测肿瘤进展并预测预后的效应生物标志物，有助于膀胱癌的临床管理并改善患者术后生活质量。本研究旨在评估长链非编码（lnc）RNA RHPN1-AS1（RHPN1-AS1）在膀胱癌中的作用及潜在分子机制。
采用聚合酶链反应评估115例患者膀胱癌组织及细胞中RHPN1-AS1的表达。评估RHPN1-AS1的临床意义，并在细胞增殖、迁移和侵袭方面评估其作用。通过双荧光素酶报告基因检测探索潜在分子机制。
RHPN1-AS1在膀胱癌中的表达升高了2.91倍，与肿瘤淋巴结转移晚期（=0.013）和淋巴结转移的存在（=0.018）密切相关。RHPN1-AS1也是膀胱癌预后不良的指标（风险比=2.563）。敲低RHPN1-AS1可显著抑制膀胱癌细胞的增殖和转移能力。此外，发现miR-485-5p介导RHPN1-AS1在膀胱癌中的功能，这被认为是潜在的调控机制。
RHPN1-AS1通过调节miR-485-5p在膀胱癌中作为预后生物标志物和肿瘤促进因子，这可能是膀胱癌治疗的可靠靶点。
